Rohit Loomba, MD
Internal Medicine · la Jolla, CANPI 1578593521
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $653,376 of the $965,207 with a category attached, or 67.7%. It is spread thinly across 45 manufacturers, the largest accounting for just 17.0%. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 417 payments — averaging $2314.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intercept Pharmaceuticals, Inc.$164K
- Novo Nordisk AS$143K
- Madrigal Pharmaceuticals$125K
- Novo Nordisk$115K
- Theratechnologies Inc.$68K
- Takeda Pharmaceuticals U.S.A., Inc.$41K
- plus $310K from 39 others
Across 545 payments — averaging $26,200 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$3.9M
- Astrazeneca UK Limited$2.4M
- Gilead$2.1M
- Astrazeneca AB$2M
- Pfizer$1.3M
- Janssen Research & Development, LLC$835K
- plus $1.8M from 17 others
What the payments were for
- Consulting fees$653,37668%
- Speaking & faculty fees$111,47612%
- Grants$69,8877%
- Travel & lodging$119,96612%
- Food & beverage$10,4721%
- Education$310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZDIFFRA$51,611
- Wegovy$18,775
- OLEZARSEN$10,022
- Repatha$4,578
- EGRIFTA$4,000
- Novoeight$3,750
- RESMETIROM$2,536
- OBETICHOLIC ACID$2,500
- ADVIA Centaur XP Analyzer$1,585
- GLASSIA$1,400
- MK-3655$443
- ADVIA Immunoassay Reagents/Test Kit/Clinical Utilization$318
- Tavneos$271
- OCALIVA$179
- KRYSTEXXA$124
- DUPIXENT$122
- UPLIZNA$122
- Austedo XR$121
- Zilretta$117
- LUPKYNIS$106
How this compares
$965,207 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RezdiffraResmetirom | 53 | $206,063 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Madrigal PharmaceuticalsRezdiffra | $124,765 | $206,06353 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in la Jolla
- Hyong Kimla Jolla$1M
- Fouad Moawadla Jolla$725K
- Lewis Rubinla Jolla$265K
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Fred CohenSan Francisco$929K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.